布里奥斯塔丁-1 通过上调 MAP 激酶 11 的调节,增强了耗尽的 CD8+ T 细胞的增殖和功能
Ling Li1, Manzhi Zhao1, Marjan van Meurs1
1Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands.
Frontiers in immunology
|January 29, 2025
概括
布里奥斯-1通过调节MAPK11活性来增强HIV特定的CD8+T细胞功能和增殖. 这一发现支持布里奥斯-1在艾滋病毒治疗策略和癌症免疫治疗方面的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 癌症生物学 癌症生物学
背景情况:
- 特定于HIV的CD8+ T细胞对于病毒清除至关重要,但往往会耗尽.
- 耗尽的CD8+ T细胞表现出减少的增殖和受损的细胞因子生产,类似于癌症中出现的功能障碍.
- 布里奥斯塔丁-1,一种蛋白质激酶C激活剂,在艾滋病毒和癌症治疗中表现出潜力.
研究的目的:
- 调查布里奥斯塔丁-1对已耗尽的HIV特异性CD8+T细胞的直接影响.
- 确定布里奥斯塔丁-1如何影响CD8+ T细胞的功能,增殖和基因表达.
- 阐明基激活蛋白激酶 (MAPK) 11在布里奥斯塔丁-1对T细胞耗尽的影响中的作用.
主要方法:
- 来自艾滋病毒感染者 (PWH) 的外周血液单核细胞 (PBMC) 用布里奥斯-1.
- 特定于艾滋病毒的CD8+ T细胞被使用四相聚变染色识别并通过流细胞计分析.
- 实验室小鼠T细胞耗尽模型被用于评估抑制受体,转录因子,细胞因子生产和杀死能力的变化.
- 进行RNA测序 (RNA-seq) 来分析转录变化.
主要成果:
- 布里奥斯塔丁-1 改善了HIV特异性CD8+ T细胞的扩张并降低了PD-1表达.
- 布里奥斯塔丁-1增强了体外生成的CD8+ T细胞的功能和增殖,同时降低了抑制性受体表达.
- 布里奥斯塔丁-1上调TCF-1和下调TOX表达,由RNA-seq.证实. RNA-seq还揭示了耗尽的细胞中MAPK11的下调,这种下调是由布里奥斯塔丁-1.
- 抑制MAPK11阻断了布里奥斯-1-诱导的增殖和IFN-γ的产生,但没有其他影响.
结论:
- 布里奥斯塔丁-1诱导了一种MAPK11依赖的增殖和功能能力的改善,耗尽的T细胞.
- 这些发现为使用布里奥斯塔丁-1来帮助在治疗期间消除艾滋病毒储存库提供了理由.
- 布里奥斯-1也可能通过功能改善耗尽的CD8+T细胞,为癌症免疫疗法做出贡献.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


